Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487943 | 1.00 | SIGMAR1 (0.54) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30487948 | 1.00 | SIGMAR1 (0.54) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23833670 | 0.95 | SIGMAR1 (0.54) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30049093 | 0.95 | SIGMAR1 (0.54) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30666950 | 0.93 | SIGMAR1 (0.55) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19041309 | 0.91 | SIGMAR1 (0.58) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29860963 | 0.91 | SIGMAR1 (0.58) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31052615 | 0.86 | SIGMAR1 (0.60) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18192167 | 0.86 | SIGMAR1 (0.60) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11704179 | 0.84 | SIGMAR1 (0.58) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | claimed |
| EP-1771446-B1 | AZAINDOLE INHIBITORS OF MTP AND APOB | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | EP | claimed |
| US-7838533-B2 | Azaindole inhibitors of MTP and ApoB | MERCK PATENT GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1771446-B1 | AZAINDOLE INHIBITORS OF MTP AND APOB | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1771446-A2 | AZAINDOLE INHIBITORS OF MTP AND APOB | Merck Patent GmbH (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010423-A2 | AZAINDOLE INHIBITORS OF MTP AND APOB | MERCK PATENT GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | APOB, MTPN, HDLBP | SIGMAR1 3262/4885TP53 3084/4885CYP1A2 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.